Nanosonics Limited (ASX:NAN) shares were priced at $2.86 on 6 October 2026, down 1.04% on the day, and are down 34.25% over the past twelve months. The infection prevention company reported its FY26 financial results on 25 August 2026 for the year ended 30 June 2026, with figures in Australian dollars.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

Nanosonics develops infection prevention products for healthcare settings. Its current Revenue base is the trophon ultrasound probe disinfection system, which generates Capital revenue from device sales and upgrades and Recurring Revenue from consumables, ecosystem products, service and spare parts. The global installed base reached 39,230 devices, with North America the main growth region.

The company is preparing a second platform, the CORIS System, for endoscope reprocessing. CORIS has been in Controlled Market Release, with sites active in Australia, the United Kingdom, Ireland and the United States, and has received approvals in Australia, Europe and the United Kingdom, along with a first FDA 510(k) clearance. Nanosonics is headquartered in Macquarie Park, New South Wales, holds no Debt and reported cash of $155.2 million.

Sector Dynamics

Infection prevention Demand is linked to procedure volumes and standards for reprocessing medical devices. Nanosonics reported that fleet modernisation is under way as customers move to newer trophon generations, noting that lower spare parts sales were consistent with this transition. The launch of trophon3 and trophon2 Plus software upgrades is part of that cycle.

Trade and currency conditions affect the sector's reported results. A strengthening Australian dollar reduced reported revenue growth to 3% against 6% in constant currency, and US tariffs of 12.5% are assumed to continue. The company recovered $2.5 million of tariffs paid under the International Emergency Economic Powers Act through February 2026, while residual FY26 tariffs were $0.6 million, compared with $0.5 million in FY25. Freight cost increases tied to geopolitical conditions are also noted.

FY26 Results Update

Revenue was $203.9 million, up 3%, or up 6% to $211.5 million in constant currency. Capital revenue was $54.7 million, up 4%, supported by 4,230 device placements, up 9%, including a record 1,980 North American upgrades, up 32%. North American placements reached a record 3,880, up 13%. Recurring revenue was $149.2 million, up 2% or 6% in constant currency, and Annuity revenue, which excludes spare parts, grew 8% in constant currency.

Gross Margin was 76.9% compared with 78.2%, reflecting product mix and currency. Operating expenses were $141.4 million, up 2%. EBIT was $16.0 million, down 10%, though up 21% to $21.6 million in constant currency. Profit before tax was $20.1 million, down 10%, or up 15% to $25.8 million in constant currency. The trophon-only Business generated EBIT of $50.6 million, up 5%, or $56.5 million and up 16% in constant currency, with the balance of the group result reflecting Investment in CORIS development and commercialisation.

The company returned $20 million through a share buyback, resulting in net cash outflows of $6.4 million, and excluding the buyback generated $13.6 million in cash. A new on-market buyback of up to $40 million has been announced for FY27.

Growth Catalysts and Critical Operating Risks

The key FY27 milestone is the commercial launch of CORIS across the United Kingdom, Ireland and Australia in the first half of FY27, with the United States launch to follow. Initial CORIS revenues are expected in the low single digit millions. FY27 guidance at constant currency is for revenue of $220 million to $228 million, growth of 8% to 12%, gross margin of 74% to 76%, and operating expenses of $156 million to $163 million, growth of 10% to 15%. The company also pointed to expected meaningful revenue from trophon2 Plus upgrades.

The release identifies cost and execution factors. Gross margin is expected to moderate because of a full twelve months of tariffs at 12.5% and higher freight costs, and operating expenses are planned to rise with the CORIS investment step-up. The guidance assumes no change in the global trading environment or current US Tariff levels. If the revenue range were recast at an average USD/AUD rate of 0.71 and allowing for hedging, it would be about $3 million lower. A second 510(k) submission for further endoscope indications has been lodged and is yet to be cleared, and the company is investing ahead of revenue from a new product category.

The release adds that Cash Flow included increased inventory investment to support growth in the trophon business and preparations for CORIS commercialisation. The company reported that its global cumulative installed base grew 6%, with 2,230 new installed base units added during the year. An investor conference call and webinar was hosted by CEO and President Michael Kavanagh and CFO Jason Burriss on 25 August 2026.

The Bottom Line

Nanosonics reports higher placements, constant currency revenue growth and trophon EBIT, alongside a reported EBIT decline of 10% and lower gross margin, with its shares down 34.25% over the year. The FY27 guidance combines revenue growth of 8% to 12% with Operating Expense growth of 10% to 15% and a stated gross margin range of 74% to 76%. The CORIS launch in the first half of FY27 and the $40 million buyback are the next announced steps.